Total therapy-based treatment for multiple myeloma-a single center experience

Hila Magen-Nativ, Ron Ram, Moshe Yeshurun, Anat Gafter-Gvili, Pia Raanani, Ofer Shpilberg

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma. For the last 4 years we have adopted the more intensified approach, previously published as total therapy 3 by the Arkansas group and used it with local modifications. This study aims to evaluate the efficacy and safety of the Arkansas protocol-based treatment outside clinical trial in a tertiary medical center in Israel. We retrospectively analyzed 23 patients. Seventy-three percent of the patients achieved very good partial remission (VGPR) before autologous stem cell transplantation (ASCT). Eighty-six percent of the patients achieved at least VGPR after tandem ASCT. Two-year overall survival was estimated as 70%. Four patients died during treatment, one as a result of disease progression. We conclude that this protocol is effective and rather safe. Further clinical trials should assess which subgroups of patients would benefit most from this approach.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalAnnals of Hematology
Volume89
Issue number1
DOIs
StatePublished - 1 Jan 2010
Externally publishedYes

Keywords

  • Autologous stem cell transplantation
  • DT-PACE
  • Myeloma
  • Total therapy

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Total therapy-based treatment for multiple myeloma-a single center experience'. Together they form a unique fingerprint.

Cite this